Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2010 3
2011 2
2012 16
2013 40
2014 61
2015 62
2016 64
2017 37
2018 58
2019 49
2020 55
2021 53
2022 44
2023 52
2024 22

Text availability

Article attribute

Article type

Publication date

Search Results

565 results

Results by year

Filters applied: . Clear all
Page 1
Vilanterol.
[No authors listed] [No authors listed] 2021 Jul 19. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2021 Jul 19. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 29999792 Free Books & Documents. Review.
Although no published data exist on the use of vilanterol during lactation, data from the related drug, terbutaline, indicate that very little is expected to be excreted into breastmilk.[1] Vilanterol is available only in combination products such as Breo Ellipta an …
Although no published data exist on the use of vilanterol during lactation, data from the related drug, terbutaline, indicate that ve …
Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis.
Ismaila AS, Haeussler K, Czira A, Youn JH, Malmenäs M, Risebrough NA, Agarwal J, Nassim M, Sharma R, Compton C, Vogelmeier CF, Han MK, Halpin DMG. Ismaila AS, et al. Adv Ther. 2022 Sep;39(9):3957-3978. doi: 10.1007/s12325-022-02231-0. Epub 2022 Jul 17. Adv Ther. 2022. PMID: 35849317 Free PMC article. Review.
This network meta-analysis (NMA) investigated the comparative efficacy of single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus any triple (ICS/LABA/LAMA) combinations and dual therapies in patients with COPD. ...
This network meta-analysis (NMA) investigated the comparative efficacy of single-inhaler fluticasone furoate/umeclidinium/vilanterol …
Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease.
Lipson DA, Crim C, Criner GJ, Day NC, Dransfield MT, Halpin DMG, Han MK, Jones CE, Kilbride S, Lange P, Lomas DA, Lettis S, Manchester P, Martin N, Midwinter D, Morris A, Pascoe SJ, Singh D, Wise RA, Martinez FJ. Lipson DA, et al. Am J Respir Crit Care Med. 2020 Jun 15;201(12):1508-1516. doi: 10.1164/rccm.201911-2207OC. Am J Respir Crit Care Med. 2020. PMID: 32162970 Free PMC article. Clinical Trial.
Rationale: The IMPACT (Informing the Pathway of Chronic Obstructive Pulmonary Disease Treatment) trial demonstrated a significant reduction in all-cause mortality (ACM) risk with fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus UMEC/VI in patients with chron …
Rationale: The IMPACT (Informing the Pathway of Chronic Obstructive Pulmonary Disease Treatment) trial demonstrated a significant reduction …
Vilanterol trifenatate for the treatment of COPD.
Malerba M, Radaeli A, Montuschi P, Morjaria JB. Malerba M, et al. Expert Rev Respir Med. 2016 Jul;10(7):719-31. doi: 10.1080/17476348.2016.1184976. Epub 2016 May 25. Expert Rev Respir Med. 2016. PMID: 27143334 Review.
Vilanterol combined in fixed-dose treatments has been tested in numerous clinical trials involving thousands of patients. ...This paper will review the clinical and experimental data regarding vilanterol use in the regular treatment of COPD as well as provide a crit …
Vilanterol combined in fixed-dose treatments has been tested in numerous clinical trials involving thousands of patients. ...This pap …
Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial.
Maltais F, Bjermer L, Kerwin EM, Jones PW, Watkins ML, Tombs L, Naya IP, Boucot IH, Lipson DA, Compton C, Vahdati-Bolouri M, Vogelmeier CF. Maltais F, et al. Respir Res. 2019 Oct 30;20(1):238. doi: 10.1186/s12931-019-1193-9. Respir Res. 2019. PMID: 31666084 Free PMC article. Clinical Trial.

RESULTS: Change from baseline in trough FEV(1) at Week 24 was 66 mL (95% confidence interval [CI]: 43, 89) and 141 mL (95% CI: 118, 164) greater with umeclidinium/vilanterol versus umeclidinium and salmeterol, respectively (both p < 0.001). ...Regardless of the clinical

…
RESULTS: Change from baseline in trough FEV(1) at Week 24 was 66 mL (95% confidence interval [CI]: 43, 89) and 141 mL (95% CI: 118, 164) gre …
Benefit of Prompt versus Delayed Use of Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Following a COPD Exacerbation.
Mannino D, Bogart M, Germain G, Huang SP, Ismaila AS, Laliberté F, Jung Y, MacKnight SD, Stiegler MA, Duh MS. Mannino D, et al. Int J Chron Obstruct Pulmon Dis. 2022 Mar 5;17:491-504. doi: 10.2147/COPD.S337668. eCollection 2022. Int J Chron Obstruct Pulmon Dis. 2022. PMID: 35281476 Free PMC article.
This study evaluated the impact of prompt versus delayed initiation of single-inhaler TT (fluticasone furoate, umeclidinium, and vilanterol [FF/UMEC/VI]) following a COPD exacerbation. PATIENTS AND METHODS: This retrospective cohort study used data from the IQVIA PharMetri …
This study evaluated the impact of prompt versus delayed initiation of single-inhaler TT (fluticasone furoate, umeclidinium, and vilanter …
Umeclidinium Bromide/Vilanterol Trifenatate (Anoro Ellipta).
[No authors listed] [No authors listed] Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Sep. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Sep. PMID: 30212060 Free Books & Documents. Review.
The objective of this review is to evaluate the beneficial and harmful effects of umeclidinium plus vilanterol (UMEC/VI) for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema....
The objective of this review is to evaluate the beneficial and harmful effects of umeclidinium plus vilanterol (UMEC/VI) for the main …
Comparative Efficacy of Umeclidinium/Vilanterol Versus Other Bronchodilators for the Treatment of Chronic Obstructive Pulmonary Disease: A Network Meta-Analysis.
Ismaila AS, Haeussler K, Czira A, Tongbram V, Malmenäs M, Agarwal J, Nassim M, Živković-Gojović M, Shen Y, Dong X, Duarte M, Compton C, Vogelmeier CF, Halpin DMG. Ismaila AS, et al. Adv Ther. 2022 Nov;39(11):4961-5010. doi: 10.1007/s12325-022-02234-x. Epub 2022 Jul 20. Adv Ther. 2022. PMID: 35857184 Free PMC article.
This systematic literature review and network meta-analysis (NMA) compared the efficacy of umeclidinium/vilanterol (UMEC/VI) versus other dual and mono-bronchodilator therapies in symptomatic patients with COPD. ...Only a few clinical trials have compared different LAMA/LA …
This systematic literature review and network meta-analysis (NMA) compared the efficacy of umeclidinium/vilanterol (UMEC/VI) versus o …
A Randomized, Double-Blind, Double-Dummy Study of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Relative to Umeclidinium/Vilanterol Dry Powder Inhaler in COPD.
Maltais F, Ferguson GT, Feldman GJ, Deslee G, Bourdin A, Fjällbrant H, Siwek-Posłuszna A, Jenkins MA, Martin UJ. Maltais F, et al. Adv Ther. 2019 Sep;36(9):2434-2449. doi: 10.1007/s12325-019-01015-3. Epub 2019 Jul 2. Adv Ther. 2019. PMID: 31267366 Clinical Trial.
We assessed the efficacy and safety of GFF MDI relative to umeclidinium/vilanterol dry powder inhaler (UV DPI) in patients with moderate-to-very severe chronic obstructive pulmonary disease (COPD). ...
We assessed the efficacy and safety of GFF MDI relative to umeclidinium/vilanterol dry powder inhaler (UV DPI) in patients with moder …
Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD.
Lipson DA, Barnhart F, Brealey N, Brooks J, Criner GJ, Day NC, Dransfield MT, Halpin DMG, Han MK, Jones CE, Kilbride S, Lange P, Lomas DA, Martinez FJ, Singh D, Tabberer M, Wise RA, Pascoe SJ; IMPACT Investigators. Lipson DA, et al. N Engl J Med. 2018 May 3;378(18):1671-1680. doi: 10.1056/NEJMoa1713901. Epub 2018 Apr 18. N Engl J Med. 2018. PMID: 29668352 Free article. Clinical Trial.
METHODS: In this randomized trial involving 10,355 patients with COPD, we compared 52 weeks of a once-daily combination of fluticasone furoate (an inhaled glucocorticoid) at a dose of 100 mug, umeclidinium (a LAMA) at a dose of 62.5 mug, and vilanterol (a LABA) at a dose o …
METHODS: In this randomized trial involving 10,355 patients with COPD, we compared 52 weeks of a once-daily combination of fluticasone furoa …
565 results